(AOF) – OSE Immunotherapeutics (+8.42% to 5.92 euros) posted one of the strongest increases in the SRD market this Monday after announcing the publication in ‘Blood’ of an article on the latest preclinical efficacy data for its product lusvertikimab (OSE-127), in the treatment of acute leukemia. “Blood” is a peer-reviewed scientific journal published by the American Society of Hematology. Lusvertikimab is able to target and block the high and deregulated expression of IL-7R in 85% of patients with acute lymphoblastic leukemia (ALL).
“We are very pleased with this publication on Lusvertikimab in ‘Blood’, a renowned journal in the field of hematology whose draft articles are evaluated by international level specialists”, comments Nicolas Poirier, general director of OSE Immunotherapeutics. “We need new targeted immunotherapy options for all patients with B- and T-cell ALL.”
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D that weigh on profitability. Sanofi has therefore announced a drop in its earnings per share in 2024 and the abandonment of its target of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to 22 billion dollars to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States will account for nearly half of global spending on oncology (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, from $5 billion to $11.8 billion.
